Sarcoma Clinical Trial
Official title:
A Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Doses of Cisplatin for Children With Peritoneal Carcinomatosis or Advanced Peritoneal and Retroperitoneal Disease
There has been no successful treatment of diffuse peritoneal metastasis or carcinomatosis,
in childhood tumors. Once this advanced stage of disease is evident, survival is measured in
weeks. The selective lethal effect of supranormal temperatures on neoplastic cells and the
additive or synergistic effect of combining chemotherapy has been well established in adult
clinical trials using continuous hyperthermic peritoneal perfusion (CHPP) for advanced
peritoneal adenocarcinoma of gastrointestinal origin, ovarian carcinoma and mesothelioma.
This phase I study will evaluate the safety of continuous hyperthermic peritoneal perfusion
with escalating doses of intraperitoneal cisplatin in the treatment of children with
refractory tumors limited to the abdominal cavity. If tumors are outside the abdominal
cavity, the tumors must be able to be controlled.
Since CHPP has potential to improve outcome of children with peritoneal and retroperitoneal
metastases, this study will evaluate the safety of elevated temperature (40oC) with
intraperitoneal cisplatin chemotherapy.
Primary Objectives:
1. To determine the MTD and dose-limiting toxicity of intraperitoneal cisplatin given in
combination with CHPP as a 90 minute perfusion in children with advanced peritoneal and
retroperitoneal solid tumors
2. To determine the safe and tolerable dose of CHPP with cisplatin to be used in Phase II
trials
3. To determine the pharmacokinetics of intraperitoneal cisplatin platinum given with CHPP
as a 90 minute abdominal perfusion (Optional)
Cisplatin has an atom at its center that contains platinum. The platinum is supposed to
poison the cancer cells, causing them to eventually die. Sodium thiosulfate is designed to
bind-up any Cisplatin that has escaped from the abdomen into the blood stream.
This is an investigational treatment which has been performed on two children on a
compassionate use basis in North America. Both surgeries were performed at M.D. Anderson by
the Study Chairman.
Before you can start receiving the study drugs, you will have "screening tests." These tests
will help the doctor decide if you are eligible to take part in this study. A physical exam
will be performed, and you will have a computed tomography (CT) scan, or magnetic resonance
imaging (MRI) scan to make sure the disease is only in the abdomen (stomach area). Blood
(about 1 teaspoon) will be drawn for routine tests. You may have an echocardiogram (ECHO--a
test to check heart function), and electrocardiogram (ECG--a test to measure electrical
activity of the heart) if you have ever taken an anthracycline drug. An echocardiogram uses
sound waves to make pictures of your heart, which helps show how well your heart pumps
blood. You will be asked to lie on your left side while a technician places a probe with gel
on your chest to create images of your heart to determine the function and size. Women who
are able to have children must have a negative urine pregnancy test.
If you are found to be eligible, you will have a hearing test before your surgery and at
your one-month evaluation.
If you are found to be eligible, the abdominal surgery will be performed to try to remove as
many tumors as possible. The surgeon may decide during the surgery that the abdominal wash
will not be performed, for example if the disease has spread to or attached to certain
organs. If this occurs, your doctor will discuss other treatment options with you.
If the doctor decides that you are eligible to receive the abdominal wash, a drug called
sodium thiosulfate will be given through a needle in your vein. The abdomen will then be
temporarily closed. Then the abdominal wash will begin. This will be done in the same room
while you are under anesthesia. During the "abdominal wash," the heated cisplatin will be
given into your abdomen and will "wash" over the area of the surgical procedure. There will
be a pump attached to the plastic tubing and that will pump the drug in and out of your
abdomen during that 90 minute period while the surgeon is gently compressing your abdominal
wall so that the drug can reach all areas of your abdomen equally. After 90 minutes the drug
is removed and your abdomen is 'washed' with saline. Then all the fluid is removed and the
surgeon permanently closes your abdomen with 3 layers of stitches.
The actual dose level of cisplatin that you will receive will be decided when you enter the
study. Participants on this study will be enrolled in groups of 3, and each group will be
given a specific dose level of cisplatin. The first group will receive the lowest dose of
cisplatin. If there are no severe or life-threatening side effects in this first group of
patients, the next group will receive a higher dose of cisplatin and so on. This process of
increasing the dose level for each new group of participants will continue until some
patients have severe or life-threatening side effects. At that point, the dose level of
cisplatin will be lowered and tested again in more participants.
Blood (about 1 teaspoon) will be drawn for routine tests. This testing will take place
during the operation and every day until you leave the hospital.
After you leave the hospital, you will have a study visit about 1 month later, and then
every 3 months for 6 months. At these visits, you will have a CT scan or MRI scan and a
physical exam to check the status of the disease.
You will be taken off study if the disease gets worse or if you are disease free at or after
your 6 month follow-up.
This is an investigational study. Cisplatin is FDA-approved and commercially available. Up
to 18 patients will take part in this study. All will be enrolled at M. D. Anderson.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
Recruiting |
NCT04457258 -
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
|
Early Phase 1 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Recruiting |
NCT04535713 -
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
|
Phase 2 | |
Completed |
NCT03521531 -
Burden and Medical Care of Sarcoma in Germany
|
||
Completed |
NCT02496520 -
Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults
|
Phase 1/Phase 2 | |
Terminated |
NCT02054104 -
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
|
Phase 1/Phase 2 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04577014 -
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT04052334 -
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
|
Phase 1 | |
Completed |
NCT01593748 -
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Recruiting |
NCT04367779 -
Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
|
||
Completed |
NCT01879085 -
Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04553692 -
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers
|
Phase 1 | |
Completed |
NCT01209598 -
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
|
Phase 2 | |
Completed |
NCT04553471 -
Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers
|
N/A | |
Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 |